Vanda Pharmaceuticals (VNDA) Projected to Post Quarterly Earnings on Thursday

Vanda Pharmaceuticals (NASDAQ:VNDA) will likely be posting its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of ($0.5825) per share and revenue of $61.9250 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.13). Vanda Pharmaceuticals had a negative return on equity of 32.26% and a negative net margin of 109.99%.The firm had revenue of $51.72 million for the quarter, compared to the consensus estimate of $54.98 million. On average, analysts expect Vanda Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vanda Pharmaceuticals Stock Performance

NASDAQ:VNDA opened at $5.22 on Tuesday. The company has a current ratio of 2.16, a quick ratio of 2.15 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average of $5.99 and a 200-day moving average of $6.90. Vanda Pharmaceuticals has a twelve month low of $4.14 and a twelve month high of $9.94. The firm has a market cap of $313.88 million, a price-to-earnings ratio of -1.29 and a beta of 0.60.

Institutional Investors Weigh In On Vanda Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Mercer Global Advisors Inc. ADV lifted its stake in shares of Vanda Pharmaceuticals by 51.2% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 43,829 shares of the biopharmaceutical company’s stock valued at $387,000 after buying an additional 14,836 shares during the period. Jane Street Group LLC raised its stake in shares of Vanda Pharmaceuticals by 6.1% in the second quarter. Jane Street Group LLC now owns 79,107 shares of the biopharmaceutical company’s stock valued at $373,000 after purchasing an additional 4,533 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Vanda Pharmaceuticals by 629.9% in the third quarter. BNP Paribas Financial Markets now owns 65,535 shares of the biopharmaceutical company’s stock worth $327,000 after purchasing an additional 56,556 shares during the period. Hsbc Holdings PLC boosted its stake in Vanda Pharmaceuticals by 17.6% during the second quarter. Hsbc Holdings PLC now owns 66,554 shares of the biopharmaceutical company’s stock worth $319,000 after buying an additional 9,960 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Vanda Pharmaceuticals by 20.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 35,283 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 6,027 shares during the period. 88.14% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

VNDA has been the topic of a number of recent research reports. Wall Street Zen cut Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. HC Wainwright restated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Thursday, June 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Friday, July 17th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.30.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.